MEDIFAST INC (MED)vsMercadoLibre Inc. (MELI)
MED
MEDIFAST INC
$12.23
-1.05%
CONSUMER CYCLICAL · Cap: $134.54M
MELI
MercadoLibre Inc.
$1,607.80
-1.65%
CONSUMER CYCLICAL · Cap: $84.81B
Smart Verdict
WallStSmart Research — data-driven comparison
MercadoLibre Inc. generates 9089% more annual revenue ($31.80B vs $346.10M). MELI leads profitability with a 6.0% profit margin vs -5.8%. MED appears more attractively valued with a PEG of 0.97. MELI earns a higher WallStSmart Score of 58/100 (C).
MED
Hold45
out of 100
Grade: D
MELI
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MED.
Margin of Safety
+61.8%
Fair Value
$5279.65
Current Price
$1607.80
$3671.85 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Revenue surging 49.0% year-over-year
Large-cap with strong market position
Every $100 of equity generates 26 in profit
Generating 1.3B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -10.1% — below average capital efficiency
Revenue declined 34.3%
Trading at 11.2x book value
6.0% margin — thin
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MED
The strongest argument for MED centers on Price/Book, Debt/Equity, Altman Z-Score. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bull Case : MELI
The strongest argument for MELI centers on Revenue Growth, Market Cap, Return on Equity. Revenue growth of 49.0% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bear Case : MED
The primary concerns for MED are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : MELI
The primary concerns for MELI are Price/Book, Profit Margin, Debt/Equity. A P/E of 44.1x leaves little room for execution misses. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Key Dynamics to Monitor
MED profiles as a turnaround stock while MELI is a hypergrowth play — different risk/reward profiles.
MELI carries more volatility with a beta of 1.41 — expect wider price swings.
MELI is growing revenue faster at 49.0% — sustainability is the question.
MELI generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
MELI scores higher overall (58/100 vs 45/100) and 49.0% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MEDIFAST INC
CONSUMER CYCLICAL · PERSONAL SERVICES · USA
Medifast, Inc. manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutrition products in the United States and Asia-Pacific. The company is headquartered in Baltimore, Maryland.
Visit Website →MercadoLibre Inc.
CONSUMER CYCLICAL · INTERNET RETAIL · USA
MercadoLibre, Inc. operates online trading platforms in Latin America. The company is headquartered in Buenos Aires, Argentina.
Compare with Other PERSONAL SERVICES Stocks
Want to dig deeper into these stocks?